Premium
STAT4‐ and STAT6‐signaling molecules in a murine model of multiple sclerosis
Author(s) -
Rodriguez Moses,
Zoecklein Laurie,
Gamez Jeffrey D.,
Pavelko Kevin D.,
Papke Louisa M.,
Nakane Shunya,
Howe Charles,
Radhakrishnan Suresh,
Hansen Michael J.,
David Chella S.,
Warrington Arthur E.,
Pease Larry R.
Publication year - 2006
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fj.05-4650fje
Subject(s) - virus , multiple sclerosis , immunology , immune system , stat4 , biology , antigen , virology , inflammation , signal transduction , stat , biochemistry , stat3
Epidemiological studies suggest that an environmental factor (possibly a virus) acquired early in life may trigger multiple sclerosis (MS). The virus may remain dormant in the central nervous system but then becomes activated in adulthood. All existing models of MS are characterized by inflammation or demyelination that follows days after virus infection or antigen inoculation. While investigating the role of CD4 + T cell responses following Theiler's virus infection in mice deficient in STAT4 or STAT6, we discovered a model in which virus infection was followed by demyelination after a very prolonged incubation period. STAT4−/− mice were resistant to demyelination for 180 days after infection, but developed severe demyelination after this time point. Inflammatory cells and up‐regulation of Class I and Class II MHC antigens characterized these lesions. Virus antigen was partially controlled during the early chronic phase of the infection even though viral RNA levels remained high throughout infection. Demyelination correlated with the appearance of virus antigen expression. Bone marrow reconstitution experiments indicated that the mechanism of the late onset demyelination was the result of the STAT4−/− immune system. Thus, virus infection of STAT4−/− mice results in a model that may allow for dissection of the immune events predisposing to late‐onset demyelination in MS.